The goal of asthma management is to achieve optimal asthma control, defined by absence of daytime symptoms, night time waking, reliever use, functional limitation and lung function stability, and to also reduce the future risks of asthma exacerbations, deterioration in lung function and medication’s side effects. The most widely used maintenance therapy is inhaled corticosteroids (ICS). This review will consider the evidence that the combination of the ICS budesonide and the rapid onset long acting beta-agonist (LABA), formoterol can be used as a standard of care for maintenance and reliever therapy in moderate to severe asthma.
The archival literature of peer-reviewed studies of the efficacy and safety of budesonide/formoterol as maintenance and reliever therapy in moderate to severe asthma.
The ICS/LABA combination containing budesonide/formoterol reduces future risk of severe asthma exacerbations, and provides similar levels of day-to-day asthma control, when compared to using high dose ICS alone, or combination ICS/LABA therapy and SABA as reliever.
Budesonide/formoterol as a single combination maintenance and reliever inhaler is effective in reducing asthma exacerbation risk, requires a lower maintenance dose of ICS, and results in a simplified approach to asthma management.
Copyright © 2020. Published by Elsevier Inc.
Asthma maintenance and reliever therapy: should this be the standard of care?
